Damian J Green

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
  2. pmc Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
  3. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
  4. pmc Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Blood 116:4231-9. 2010
  5. pmc Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America Hematology Division, University of Washington, Seattle, WA, United States of America
    PLoS ONE 9:e113601. 2014
  6. pmc Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 121:3759-67. 2013
  7. pmc Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Clin Cancer Res 17:7373-82. 2011
  8. pmc Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA Departments of Medicine and
    Blood 125:2111-9. 2015
  9. pmc In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model
    Ethan R Balkin
    Radiation Oncology, University of Washington, Seattle, Washington
    Cancer Res 74:5846-54. 2014
  10. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
    ..We are optimistic that this novel approach will provide a meaningful prolongation of survival for patients with relapsed or refractory lymphomas...
  2. pmc Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:1226-35. 2009
    ..These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma...
  3. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
    ..These data suggest that anti-CD45 PRIT using an α-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia...
  4. pmc Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Blood 116:4231-9. 2010
    ..0001). Treatment was well tolerated, with no treatment-related mortalities. This study demonstrates the favorable biodistribution profile and excellent therapeutic efficacy attainable with ²¹³Bi-labeled anti-CD20 PRIT...
  5. pmc Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America Hematology Division, University of Washington, Seattle, WA, United States of America
    PLoS ONE 9:e113601. 2014
    ..Conversely, 177Lu- anti-CD45 RIT yielded no long-term survivors. Thus, 90Y was more effective than 177Lu for anti-CD45 RIT of AML in this murine leukemia model...
  6. pmc Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
    Johnnie J Orozco
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 121:3759-67. 2013
    ..7 K/µL 2 weeks after HSCT and recovery by 4 weeks. These data suggest that (211)At-anti-CD45 RIT in conjunction with HSCT may be a promising therapeutic option for AML...
  7. pmc Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma
    Steven I Park
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    Clin Cancer Res 17:7373-82. 2011
    ..We engineered a series of SAv FPs that downmodulate the affinity of SAv for biotin, while retaining high avidity for divalent DOTA-bis-biotin to circumvent this problem...
  8. pmc Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA Departments of Medicine and
    Blood 125:2111-9. 2015
    ..These findings suggest that α-emitters are highly efficacious in MRD settings, where isolated cells and small tumor clusters prevail. ..
  9. pmc In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model
    Ethan R Balkin
    Radiation Oncology, University of Washington, Seattle, Washington
    Cancer Res 74:5846-54. 2014
    ..Overall, our findings offer a preclinical proof of concept for the use of CLI techniques in tandem with currently available clinical diagnostic tools...
  10. pmc A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:4903-13. 2009
    ..We hypothesize that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of survival for patients with relapsed lymphomas compared with currently available treatment strategies...
  11. pmc Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
    Sofia H L Frost
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
    PLoS ONE 10:e0120561. 2015
    ..We therefore compared the therapeutic potential of targeting either 90Y or 177Lu to human B-cell lymphoma xenografts in mice...
  12. pmc Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington
    Biol Blood Marrow Transplant 21:281-7. 2015
    ..In conclusion, despite relatively high rates of GVHD, patients with persistent iB-NHL can derive durable benefit from NMAT...
  13. pmc Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity
    Colin Phipps
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leuk Lymphoma 56:92-6. 2015
    ..11, p = 0.01). Pre-transplant rituximab-sensitivity is a strong independent predictor of post-transplant outcomes in relapsed FL, although one-third of RR patients achieved a PFS of over 3 years with ASCT...
  14. pmc Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 19:1403-6. 2013
    ..These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT...
  15. pmc Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation
    Andrew J Cowan
    aClinical Research Division, Fred Hutchinson Cancer Research Center bDepartment of Medicine, Division of Medical Oncology, University of Washington cSeattle Genetics Inc, Seattle, Washington, USA
    Anticancer Drugs 26:974-83. 2015
    ..Bortezomib and fenretinide exhibit synergistic cytotoxicity against MCL cell lines. This activity is mediated by IκBα kinase modulation, decreased cyclin expression, cell cycle dysregulation, and apoptotic cell death. ..
  16. pmc Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome
    Raya Mawad
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington
    Biol Blood Marrow Transplant 20:1363-8. 2014
    ..Moreover, the arbitrary limit of 43 Gy to the marrow may be unnecessarily conservative, and continued escalation of targeted radioimmunotherapy doses may be feasible to further reduce relapse. ..
  17. pmc Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
    Lihua E Budde
    825 Eastlake Ave E, G3 200, Seattle, WA, USA
    J Clin Oncol 29:3023-9. 2011
    ....
  18. pmc Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
    Ajay K Gopal
    Department of Medicine, University of Washington, Box 358081, 825 Eastlake Ave E, MS G3200, Seattle, WA, USA
    Invest New Drugs 32:1213-25. 2014
    ..This study evaluated the safety, pharmacokinetics, and efficacy of otlertuzumab administered in combination with rituximab and bendamustine to patients with relapsed, indolent B-cell non-Hodgkin Lymphoma (NHL)...
  19. pmc Pulmonary embolization of fat and bone marrow in cynomolgus Macaques (Macaca fascicularis)
    Derek L Fong
    Washington National Primate Research Center, University of Washington, USA
    Comp Med 61:86-91. 2011
    ..FE and FES represent important research confounders and FES should be considered as a differential diagnosis for clinical complications subsequent to skeletal trauma...
  20. doi request reprint Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies
    Eneida R Nemecek
    Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
    Cancer Biother Radiopharm 23:181-91. 2008
    ..We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model...